Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25240402 | 0.94 | ADRA1A (0.59) | ADRA1ADRD2DRD3HTR2AHTR1D | |
| SCHEMBL30510686 | 0.94 | ADRA1A (0.59) | ADRA1ADRD2DRD3HTR2AHTR1D | |
| SCHEMBL30510684 | 0.94 | ADRA1A (0.59) | ADRA1ADRD2DRD3HTR2AHTR1D | |
| SCHEMBL30510689 | 0.86 | ADRA1A (0.65) | ADRA1ADRD2DRD3HTR1DHTR1B | |
| SCHEMBL25285673 | 0.86 | ADRA1A (0.65) | ADRA1ADRD2DRD3HTR1DHTR1B | |
| SCHEMBL7544871 | 0.85 | ADRA1A (0.59) | ADRA1ADRD2DRD3HTR2AHTR2C | |
| SCHEMBL24733607 | 0.83 | ADRA1A (0.61) | ADRA1ADRD2DRD3HTR2AHTR1D | |
| SCHEMBL25289635 | 0.82 | ADRA1A (0.59) | ADRA1ADRD2DRD3HTR2AHTR1D | |
| SCHEMBL25757255 | 0.82 | ADRA1A (0.59) | ADRA1ADRD2DRD3HTR2AHTR1D | |
| SCHEMBL25757597 | 0.82 | ADRA1A (0.59) | ADRA1ADRD2DRD3HTR2AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282708-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI THERAPEUTICS, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-12344570-B2 | Aminotetraline activators of serotonin receptors | ATAI THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4457203-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240300885-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2024-09-12 | — | — | US | disclosed |
| US-11827580-B2 | Aminotetraline activators of serotonin receptors | ATAI Life Sciences AG (DE) | 2023-11-28 | — | — | US | disclosed |
| US-11827580-B2 | Aminotetraline activators of serotonin receptors | ATAI Life Sciences AG (DE) | 2023-11-28 | — | — | US | disclosed |
| US-11827580-B2 | Aminotetraline activators of serotonin receptors | ATAI Life Sciences AG (DE) | 2023-11-28 | — | — | US | disclosed |
| WO-2023129909-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129909-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Life Sciences AG (DE) | 2023-07-06 | — | — | WO | disclosed |
| US-20230202965-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ENTHEOGENIX BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202965-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ENTHEOGENIX BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202965-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | ENTHEOGENIX BIOSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300885-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR3B, HTR1B, TAAR5 | ADRA1A 32/4885DRD2 111/4885DRD3 273/4885 |
| US-20250282708-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR3B, HTR1B, TAAR5 | ADRA1A 32/4885DRD2 111/4885DRD3 273/4885 |
| US-12344570-B2 | Aminotetraline activators of serotonin receptors | HTR3B, HTR1B, TAAR5 | ADRA1A 32/4885DRD2 111/4885DRD3 273/4885 |
| US-11827580-B2 | Aminotetraline activators of serotonin receptors | HTR3B, HTR1B, TAAR5 | ADRA1A 28/4885DRD2 98/4885DRD3 266/4885 |
| US-20230202965-A1 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR3B, HTR1B, TAAR5 | ADRA1A 32/4885DRD2 111/4885DRD3 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.